Trials / Completed
CompletedNCT06114745
A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of SHR-1707 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Atridia Pty Ltd. · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1707 in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD for 26 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1707 injection | Drug: SHR-1707 SHR-1707 will be administered through IV infusion. Drug: Placebo Placebo will be administered through IV infusion |
| DRUG | Placebo | Placebo will be administered through IV infusion |
Timeline
- Start date
- 2024-04-17
- Primary completion
- 2025-07-08
- Completion
- 2025-07-08
- First posted
- 2023-11-02
- Last updated
- 2025-07-11
Locations
3 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT06114745. Inclusion in this directory is not an endorsement.